Thomas Katie L, Bellenie Benjamin R, Rossanese Olivia W
Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K..
Chimia (Aarau). 2025 Mar 26;79(3):162-166. doi: 10.2533/chimia.2025.162.
Monovalent degraders can enhance pre-existing surface complementarity between a target protein and a ligase to induce target degradation via the proteasome. For the most part, degraders have been discovered serendipitously and structure-activity relationship (SAR) studies have been limited, making it difficult to rationally design new compounds. Here we discuss how work on the SAR of cyclin K degraders demonstrates that a broad range of compounds can stabilise protein-protein interactions to induce degradation and how it lays the foundation for further monovalent degrader discovery.
单价降解剂可以增强目标蛋白与连接酶之间预先存在的表面互补性,以通过蛋白酶体诱导目标降解。在很大程度上,降解剂是偶然发现的,结构-活性关系(SAR)研究有限,这使得合理设计新化合物变得困难。在这里,我们讨论细胞周期蛋白K降解剂的SAR研究如何表明广泛的化合物可以稳定蛋白质-蛋白质相互作用以诱导降解,以及它如何为进一步发现单价降解剂奠定基础。